Literature DB >> 17785580

Evidence for functional P2X4/P2X7 heteromeric receptors.

Chang Guo1, Marianela Masin, Omar S Qureshi, Ruth D Murrell-Lagnado.   

Abstract

The cytolytic ionotropic ATP receptor P2X7 has several important roles in immune cell regulation, such as cytokine release, apoptosis, and microbial killing. Although P2X7 receptors are frequently coexpressed with another subtype of P2X receptor, P2X4, they are believed not to form heteromeric assemblies but to function only as homomers. Both receptors play a role in neuropathic pain; therefore, understanding how they coordinate the cellular response to ATP is important for the development of effective pain therapies. Here, we provide biochemical and electrophysiological evidence for an association between P2X4 and P2X7 that increases the diversity of receptor currents mediated via these two subtypes. The heterologously expressed receptors were coimmunoprecipitated from human embryonic kidney (HEK) 293 cells, and the endogenous P2X4 and P2X7 receptors were similarly coimmunoprecipitated from bone marrow-derived macrophages. In HEK293 cells, the fraction of P2X4 receptors biotinylated at the plasma membrane increased 2-fold in the presence of P2X7 although there was no change in overall expression. Coexpression of a dominant-negative P2X4 mutant (C353W) with P2X7, inhibited P2X7 receptor mediated currents by greater than 2-fold, whereas a nonfunctional but non-dominant-negative mutant (S341W) did not. Coexpression of P2X4S341W with P2X7 produced a current that was potentiated by ivermectin and inhibited by 2',3'-O-(2,4,6-trinitrophenyl) adenosine 5-triphosphate (TNP-ATP), whereas expression of P2X7 alone produced a current that was insensitive to both of these compounds at the concentrations used. These results demonstrate a structural and functional interaction between P2X4 and P2X7, which suggests that they associate to form heteromeric receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785580     DOI: 10.1124/mol.107.035980

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  90 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

2.  P2X4 receptors influence inflammasome activation after spinal cord injury.

Authors:  Juan Pablo de Rivero Vaccari; Dominic Bastien; Geoffrey Yurcisin; Isabelle Pineau; W Dalton Dietrich; Yves De Koninck; Robert W Keane; Steve Lacroix
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

3.  Damage-induced cell-cell communication in different cochlear cell types via two distinct ATP-dependent Ca waves.

Authors:  Manuela Lahne; Jonathan E Gale
Journal:  Purinergic Signal       Date:  2010-07-06       Impact factor: 3.765

4.  Electrophysiological classification of P2X7 receptors in rat cultured neocortical astroglia.

Authors:  W Nörenberg; J Schunk; W Fischer; H Sobottka; T Riedel; J F Oliveira; H Franke; P Illes
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

5.  Activation of P2X receptors induces apoptosis in human retinal pigment epithelium.

Authors:  Dongli Yang; Susan G Elner; Andrea J Clark; Bret A Hughes; Howard R Petty; Victor M Elner
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-18       Impact factor: 4.799

6.  Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures.

Authors:  Niklas R Jørgensen; Lise B Husted; Kristen K Skarratt; Leanne Stokes; Charlotte L Tofteng; Torben Kvist; Jens-Erik B Jensen; Pia Eiken; Kim Brixen; Stephen Fuller; Rory Clifton-Bligh; Alison Gartland; Peter Schwarz; Bente L Langdahl; James S Wiley
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

Review 7.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 8.  P2X receptor channels in chronic pain pathways.

Authors:  Louis-Philippe Bernier; Ariel R Ase; Philippe Séguéla
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

9.  P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control.

Authors:  Tobias Engel; Alba Jimenez-Pacheco; Maria Teresa Miras-Portugal; Miguel Diaz-Hernandez; David C Henshall
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

10.  Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors.

Authors:  Andrea Babelova; Kristin Moreth; Wasiliki Tsalastra-Greul; Jinyang Zeng-Brouwers; Oliver Eickelberg; Marian F Young; Peter Bruckner; Josef Pfeilschifter; Roland M Schaefer; Hermann-Josef Gröne; Liliana Schaefer
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.